U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07815808) titled 'Cardioprotective Effect of Empagliflozin in Breast Cancer Patients' on Sept. 07.
Brief Summary: Background: Doxorubicin (DOX) remains a cornerstone in adjuvant and neoadjuvant therapy for breast cancer, but its utility is hindered by dose-dependent cardiotoxicity. Both SGLT2 inhibitors (Empagliflozin) and Biguanides (Metformin) have demonstrated off-target cardioprotective and metabolic properties in preclinical and clinical settings.
Objective: To compare the cardioprotective efficacy, safety, and metabolic/oncologic outcomes of Empagliflozin versus Metformin in non-diabetic or controlled-diabetic women with breast cancer undergo...